SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Human & Experimental Toxicology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Alexander, D.
Right arrow Articles by Wilson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alexander, D.
Right arrow Articles by Wilson, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

HFA-134a (1 ,1, 1, 2-tetrafluoroethane): lack of oncogenicity in rodents after inhalation

DJ Alexander

Medicines Safety Evaluation Division, Glaxo Research and Development Ltd., Ware, Hertfordshire, SG12 0DP, UK

SE Libretto

Medicines Safety Evaluation Division, Glaxo Research and Development Ltd., Ware, Hertfordshire, SG12 0DP, UK

H-J. Chevalier

Experimental Pathology Services AG, Hauptstrasse 77a, CH-4132 Muttenz, Switzerland

T. Imamura

Research and Consulting Company Ltd., PO Box, CH-1227 Carouge/Geneva, Switzerland

G. Pappritz

Patco, Experimental Pathology Consulting AG, Landstrasse 15, CH-4452 Itingen, Switzerland

J. Wilson

Research and Consulting Company Ltd., Postfach, CH-4452 Itingen, Switzerland

1 Groups of 60 male and 60 female B6C3F1 mice or Han- Ibm Wistar rats were exposed to HFA-134a using snout- only inhalation exposure techniques for periods of one hour daily for at least 104 weeks. HFA-134a was deliv ered directly from cylinders at vapour concentrations of 2500, 15 000 and 75 000ppm for mice and from metered-dose inhalers at vapour concentrations of 2500, 10 000 and 50 000ppm for rats.

2 Intended dosages were achieved.

3 Evidence of absorption was found at each dose level and was dose related.

4 Neither species suffered any treatment related effects on survival, clinical signs, body weights, haematology nor on the type, incidence, site or severity of gross lesions.

5 There was no effect of treatment on the type, incidence, site or severity of neoplasms in mice or rats.

6 There were no non-neoplastic findings related to treat ment in mice.

7 HFA-134a was considered not to be oncogenic and to provide a safe alternative to chlorofluorocarbons for use in pharmaceutical metered-dose inhalers.

Key Words: HFA-134a • propellant • oncogenicity • inhalation • rodents

Human & Experimental Toxicology, Vol. 14, No. 9, 706-714 (1995)
DOI: 10.1177/096032719501400902
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
R. S. Thomas, W. Bao, T.-M. Chu, M. Bessarabova, T. Nikolskaya, Y. Nikolsky, M. E. Andersen, and R. D. Wolfinger
Use of Short-term Transcriptional Profiles to Assess the Long-term Cancer-Related Safety of Environmental and Industrial Chemicals
Toxicol. Sci., December 1, 2009; 112(2): 311 - 321.
[Abstract] [Full Text] [PDF]


Advertisement